
EDAP TMS (EDAP) Stock Forecast & Price Target
EDAP TMS (EDAP) Analyst Ratings
Bulls say
Edap TMS has recorded a significant 63% year-over-year increase in procedure volume within its HIFU division, reflecting strong market adoption among urologists and enhancing revenue contribution from disposable products. The company is poised for future growth due to recent developments, including the favorable presentation of HIFI study results at major annual meetings and the attainment of reimbursement approval in Switzerland, which enhances its commercial presence in Europe and the Middle East. Additionally, the positive outcomes reported in clinical studies—such as reductions in pelvic pain scores and endometriosis nodule volumes—bolster the long-term potential for HIFU technology, further supporting the company's growth trajectory.
Bears say
Edap TMS SA reported a decline in HIFU-related revenue, reaching €4.8 million in the second quarter of 2024, down from €4.9 million in the same quarter of the previous year, which can be attributed to unrealized revenues from system placements. Additionally, the interim results of a study concerning the use of HIFU treatment for endometriosis fell short of the primary endpoint of reducing acute pelvic pain, raising concerns about the therapy's effectiveness and potential market acceptance. Collectively, these factors suggest underlying challenges within the HIFU division that may negatively impact Edap TMS's overall financial performance and growth prospects.
This aggregate rating is based on analysts' research of EDAP TMS and is not a guaranteed prediction by Public.com or investment advice.
EDAP TMS (EDAP) Analyst Forecast & Price Prediction
Start investing in EDAP TMS (EDAP)
Order type
Buy in
Order amount
Est. shares
0 shares